4.8 Article

The schizophrenia-associated variant in SLC39A8 alters protein glycosylation in the mouse brain

Journal

MOLECULAR PSYCHIATRY
Volume 27, Issue 3, Pages 1405-1415

Publisher

SPRINGERNATURE
DOI: 10.1038/s41380-022-01490-1

Keywords

-

Funding

  1. Stanley Center for Psychiatric Research at the Broad Institute of Harvard/MIT
  2. NIH [P41GM103694, R24GM137763, P30DK040561]
  3. Dupont Warren Fellowship
  4. NIH NCI [U01CA242098]
  5. [T32MH112485]

Ask authors/readers for more resources

The missense mutation A391T in SLC39A8 is strongly associated with schizophrenia, and this study reveals its impact on protein glycosylation in the brain. This finding provides a mechanistic link between the risk allele and reversible biochemical changes, offering a new understanding of the molecular pathophysiology of schizophrenia and a potential avenue for therapeutic development.
A missense mutation (A391T) in SLC39A8 is strongly associated with schizophrenia in genomic studies, though the molecular connection to the brain is unknown. Human carriers of A391T have reduced serum manganese, altered plasma glycosylation, and brain MRI changes consistent with altered metal transport. Here, using a knock-in mouse model homozygous for A391T, we show that the schizophrenia-associated variant changes protein glycosylation in the brain. Glycosylation of Asn residues in glycoproteins (N-glycosylation) was most significantly impaired, with effects differing between regions. RNAseq analysis showed negligible regional variation, consistent with changes in the activity of glycosylation enzymes rather than gene expression. Finally, nearly one-third of detected glycoproteins were differentially N-glycosylated in the cortex, including members of several pathways previously implicated in schizophrenia, such as cell adhesion molecules and neurotransmitter receptors that are expressed across all cell types. These findings provide a mechanistic link between a risk allele and potentially reversible biochemical changes in the brain, furthering our molecular understanding of the pathophysiology of schizophrenia and a novel opportunity for therapeutic development.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available